Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02141438 · ClinicalTrials.gov registry record

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

A clinical trial of Metastatic Castration-Resistant Prostate Cancer, sponsored by Bayer.

Completed
Registry status
1,472
Enrollment target
20
Study locations

NCT02141438: Completed study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Bayer.

NCT02141438 is a study of Metastatic Castration-Resistant Prostate Cancer that has completed, run by Bayer. The registered enrollment target is 1,472 participants, above the 177-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (732% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02141438, a study of Metastatic Castration-Resistant Prostate Cancer, has completed, sponsored by Bayer.

COMPLETED
Registry status
1,472 participants
Enrollment target
20
Study locations

Study Summary

Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.

Primary Outcome

Second primary malignancies (SPMs) are defined as new malignancies unrelated to prostate cancer or progression of prostate cancer. All types of SPMs will be collected irrespectively of their relationship to Radium-223. All reported SPMs will be summarized as assessed by the physician

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Radium-223 dichloride (Xofigo, BAY88-8223)

Study Locations (20)

Florida

  • - Boca Raton
  • - Fort Myers
  • - Jacksonville
  • - Lakewood Rch
  • - Plantation

California

  • - Daly City
  • - Long Beach
  • - Sacramento
  • - San Diego

Georgia

  • - Atlanta
  • - Decatur

Illinois

  • - Evanston
  • - Warrenville

Alaska

  • - Anchorage

Arizona

  • - Scottsdale

Colorado

  • - Colorado Springs

Hawaii

  • - Honolulu

Trial Details

FieldValue
Enrollment Target 1,472 participants
Start Date 2014-08-20
Est. Completion 2024-10-24
Bayer

591 total trials

What the finished NCT02141438 record still lists

NCT02141438 is an observational study that tracks outcomes without assigning an intervention. Its 1,472 participants enrollment target places it among the larger protocols in the corpus, above the 177-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (732% higher).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radium-223 dichloride (Xofigo, BAY88-8223) is the first listed.

NCT02141438 names 20 study sites across 11 states, led by Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT02141438 about?

NCT02141438 is a clinical study titled "Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer". Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.

What is the current status of trial NCT02141438?

This trial is currently completed. The enrollment target is 1,472 participants. The study started on 2014-08-20. Estimated completion is 2024-10-24.

What conditions does trial NCT02141438 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT02141438?

The interventions under investigation include: Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG).

Who is sponsoring clinical trial NCT02141438?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02141438 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02141438's enrollment target sits among peer trials

1,472 1st of 69 higher than 69 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05869552 · 1,485 participants · NA

    Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care

  • NCT03936361 · 1,456 participants · Phase 3

    Statins In Intracerbral Hemorrhage

  • NCT06782347 · 1,454 participants · NA

    Activating SilverSneakers Benefits for Seniors With Osteoarthritis

  • NCT04566328 · 1,450 participants · Phase 3

    Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02141438, the US trial registry maintained by the National Library of Medicine. NCT02141438 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.